-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 2, Broad Pharmaceuticals announced that Telix Pharmaceuticals Limited (ASX: TLX), a global innovative radionuclide conjugated drug for prostate cancer imaging, TLX591-CDx, the group’s partner in the field of radionuclide conjugated drugs (RDC) (Illuccix®, 68Ga-HBED-CC-PSMA11) A clinical study in Japan recently completed the first patient administration; the radionuclide conjugate drug TLX591 (177Lu-DOTA-Rosopatamab) for the treatment of prostate cancer was approved for phase III The clinical research was approved by the Human Research Ethics Committee (Human Research Ethics Committee).
Yuanda Pharmaceuticals stated that Telix’s TLX591-CDx and TLX591, and another product TLX599 (99mTc-EDDA/HYNIC-iPSMA) are a global innovative molecular targeted radiation (MTR) product portfolio integrating radiological diagnosis and treatment of prostate cancer, with precise delivery The triple advantages of radionuclide, systemic drug delivery and imaging plus therapy.
Among them, TLX591-CDx is a globally innovative, radionuclide-antibody coupling technology-based diagnostic radiopharmaceutical targeting prostate specific membrane antigen (PSMA), suitable for the diagnosis of metastatic prostate cancer and recurrent prostate cancer .
The clinical study of TLX591-CDx in Japan was jointly carried out by Telix and Kanazawa University.
TLX591 is a therapeutic radiopharmaceutical targeting PSMA target based on radionuclide-antibody coupling technology, and has shown good safety and effectiveness in the completed phase II clinical trial.
Radionuclide drugs are one of the strategic directions of Broad Pharmaceutical's key deployment in the field of anti-tumor.
It is worth noting that the National Comprehensive Cancer Network prostate cancer guide (2020 edition) recommends TLX591-CDx as a new type of positron radiopharmaceutical (PET tracer), compared to other approved tracers The detection effect of recurrence is better in patients with low PSA levels.
